ArticleCureus2025
Navigating Calciphylaxis in End-Stage Renal Disease: A Case Report Highlighting the Complexities of Pain Control and the Need for Greater Clinical Vigilance.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present this case to increase awareness of calciphylaxis to promote early diagnosis and, therefore, improved clinical outcomes. Calciphylaxis is a rare, life-threatening complication of end-stage renal disease (ESRD) characterised by vascular calcification, thrombosis, and skin necrosis. We describe a 48-year-old female on long-term haemodialysis with obesity and prior warfarin use who developed painful abdominal plaques progressing to necrotic ulcers over six weeks. A skin biopsy performed at seven weeks confirmed focal calciphylaxis. Management involved intensified haemodialysis, intravenous sodium thiosulfate (12.5 g five times a week), and switching from warfarin to apixaban (2.5 mg twice daily). Despite specialist input and multimodal analgesia with opioids and adjuvant agents, pain control remained extremely challenging and significantly impacted quality of life. The case highlights the need for early recognition, prompt multidisciplinary management, and greater awareness among healthcare professionals of the severe pain burden and high morbidity associated with calciphylaxis to facilitate timely diagnosis and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.